Table.
Prevalence of anal HSIL+ in MSM
|
Anal HSIL+ in all MSM (n=12 577) |
HPV16-positive anal HSIL+*in all MSM (n=12 577) |
Anal HSIL+ in HPV16-positive MSM (n=3409) |
|||||
|---|---|---|---|---|---|---|---|
| n/N (%) | aPR (95% CI) | n/N (%) | aPR (95% CI) | n/N (%) | aPR (95% CI) | ||
| Age group, years | .. | .. | .. | .. | .. | .. | |
| 15–24 | 72/794 (9·1%) | 0·98 (0·78–1·22) | 23/794 (2·9%) | 0·76 (0·50–1·17) | 23/183 (12·6%) | 0·89 (0·62–1·29) | |
| 25–34 | 452/2847 (15·9%) | 1 (ref) | 200/2847 (7·0%) | 1 (ref) | 200/847 (23·6%) | 1 (ref) | |
| 35–44 | 725/3307 (21·9%) | 1·00 (0·91–1·10) | 334/3307 (10·1%) | 0·99 (0·84–1·17) | 334/965 (34·6%) | 1·13 (0·99–1·28) | |
| 45–54 | 778/3278 (23·7%) | 0·95 (0·86–1·05) | 343/3278 (10·5%) | 0·90 (0·76–1·07) | 343/903 (38·0%) | 1·09 (0·95–1·24) | |
| ≥55 | 480/2351 (20·4%) | 0·89 (0·79–0·99)† | 221/2351 (9·4%) | 0·91 (0·75–1·10) | 221/511 (43·2%) | 1·19 (1·03–1·36)† | |
| Age, per 10 years | .. | 0·96 (0·94–0·99)† | .. | 0·97 (0·92–1·02) | .. | 1·05 (1·01–1·09)† | |
| HIV status | .. | .. | .. | .. | .. | .. | |
| Negative | 314/2785 (11·3%) | 1 (ref) | 138/2785 (5·0%) | 1 (ref) | 138/514 (26·8%) | 1 (ref) | |
| Positive | 2193/9792 (22·4%) | 1·54 (1·36–1·73)† | 983/9792 (10·0%) | 1·66 (1·36–2·03)† | 983/2895 (34·0%) | 1·19 (1·04–1·37)† | |
PRs were adjusted for study, age group, and HIV status, as appropriate. aPR=adjusted prevalence ratio. HPV=human papillomavirus. HSIL+=high-grade squamous intraepithelial lesions or worse. MSM=men who have sex with men.
*
Only includes participants with HSIL+ plus HPV16-positive swabs.
†
Significant aPRs relative to the reference group.